SCHEMBL22209269

SCHEMBL22209269

CC(C)C1CC12CCN(C)CC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19008943 0.80 HRH3 (0.38) —
SCHEMBL23789031 0.80 SCN1A (0.32) —
SCHEMBL22248969 0.80 — —
SCHEMBL26999531 0.80 — —
SCHEMBL22305872 0.77 KDM4E (0.34) —
SCHEMBL23435072 0.75 CYP2D6 (0.46) —
SCHEMBL24455338 0.74 HRH3 (0.31) —
SCHEMBL24819398 0.72 HRH3 (0.33) —
SCHEMBL14497312 0.72 HRH3 (0.33) —
SCHEMBL23435073 0.71 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022078407-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2022-04-21 — — WO disclosed
US-20210047290-A1 SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) 2021-02-18 — — US disclosed
WO-2021022163-A2 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-02-04 — — WO disclosed
WO-2020160193-A2 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 — — WO disclosed
WO-2020160198-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 — — WO disclosed
US-10711000-B2 Autotaxin inhibitors and uses thereof FRONTHERA U.S. PHARMACEUTICALS LLC (US) 2020-07-14 — — US disclosed
Send feedback